[artículo] 
inThe American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 12 (Diciembre) . - pp. 947-958

Título :	Double-blind, sham-controlled randomized trial testing the efficacy of fmri neurofeedback on clinical and cognitive measures in children with adhd
Tipo de documento:	texto impreso
Autores:	Sheut-Ling Lam, Autor ; Marion Criaud, Autor ; Steve Lukito, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 947-958
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Trastornos del neurodesarrollo, Trastorno por déficit de atención e hiperactividad (TDAH), Neuroimagen, Neurorretroalimentación
Resumen:	Functional MRI neurofeedback (fMRI-NF) could potentially be a novel, safe nonpharmacological treatment for attention deficit hyperactivity disorder (ADHD). A proof-of-concept randomized controlled trial of fMRI-NF of the right inferior frontal cortex (rIFC), compared to an active control condition, showed promising improvement of ADHD symptoms (albeit in both groups) and in brain function. However, comparison with a placebo condition in a larger trial is required to test efficacy.
Link:	./index.php?lvl=notice_display&id=29784

[artículo] Double-blind, sham-controlled randomized trial testing the efficacy of fmri neurofeedback on clinical and cognitive measures in children with adhd [texto impreso] / Sheut-Ling Lam, Autor ; Marion Criaud, Autor ; Steve Lukito, Autor . - 2023 . - pp. 947-958.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 12 (Diciembre) . - pp. 947-958

Palabras clave:	Trastornos del neurodesarrollo, Trastorno por déficit de atención e hiperactividad (TDAH), Neuroimagen, Neurorretroalimentación
Resumen:	Functional MRI neurofeedback (fMRI-NF) could potentially be a novel, safe nonpharmacological treatment for attention deficit hyperactivity disorder (ADHD). A proof-of-concept randomized controlled trial of fMRI-NF of the right inferior frontal cortex (rIFC), compared to an active control condition, showed promising improvement of ADHD symptoms (albeit in both groups) and in brain function. However, comparison with a placebo condition in a larger trial is required to test efficacy.
Link:	./index.php?lvl=notice_display&id=29784